The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NAPISTAR 1-01: An international phase I/II trial of the novel ADC TUB-040 in platinum-resistant ovarian cancer (PROC) and relapsed/refractory adenocarcinoma non-small cell lung cancer (NSCLC).
 
Toon Van Gorp
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BioNTech SE (Inst); Daiichi Sankyo (Inst); Eisai Europe (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); MSD/Merck (Inst); OncXerna Therapeutics (Inst); Seagen (Inst); Tubulis GmbH (Inst); Zentalis (Inst)
Speakers' Bureau - Abbvie (Inst); AstraZeneca (Inst); Eisai (Inst); GlaxoSmithKline (Inst); MSD (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); MSD/Merck (Inst); PharmaMar (Inst)
 
Antonio Gonzalez Martin
Consulting or Advisory Role - Abbvie; Alkermes; Amgen; AstraZeneca; BioNTech SE; Clovis Oncology; Daiichi Sankyo; Eisai; Genmab; Hedera Dx; Immunogen; Incyte; Kartos Therapeutics; Macrogenics; Mersana; MSD; Novartis; Novocure; Oncoinvent; Pfizer/EMD Serono; Pharma&; Regeneron; Roche; Seagen; SOTIO; Sutro Biopharma; Takeda; Tesaro/GSK; Torl Biotherapeutics; Tubulis GmbH
Speakers' Bureau - AstraZeneca; Clovis Oncology; MSD Oncology; PHARMA&; PharmaMar; Roche; Tesaro/GSK
Research Funding - Roche (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; PharmaMar; Roche; Tesaro/GSK
 
Shiraj Sen
No Relationships to Disclose
 
Jalid Sehouli
Honoraria - Abbvie; Amgen; AstraZeneca; Bayer; Clovis Oncology; Corcept Therapeutics; Daiichi; Eisai; Esteve Pharmaceuticals; Gilead Sciences; GlaxoSmithKline; Hexal; Incyte; Jenapharm; Johnson & Johnson; Kyowa Kirin International; Medtronic Covidien; MSD Oncology; Myriad Pharmaceuticals; Novartis; Oncoinvent; Pfizer; PharmaMar; Phytolife Nutrition; Roche; Vifor Pharma
Consulting or Advisory Role - Alkermes; AstraZeneca; Bayer/Vital; Bristol Myers Squibb; Clovis Oncology; Corcept Therapeutics; Daiichi Sankyo; Eisai; GlaxoSmithKline; Immunogen; Ingress Health; Intuitive Surgical; Johnson & Johnson; Karyopharm Therapeutics; Lilly; Merck; MSD Oncology; Mundipharma; Novocure; Oncoinvent; Pfizer; PharmaMar; Roche; Sanofi Aventis GmbH; Seagen; Sobi; Tubulis GmbH
Research Funding - AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); IQvia (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); MSD Oncology (Inst); Mural (Inst); Pfizer (Inst); PharmaMar (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Clovis Oncology; MSD Oncology; Olympus; PharmaMar; Roche Pharma AG
 
Alex Spira
Leadership - Next Oncology (Inst)
Honoraria - Abbvie; Abbvie; Abbvie; Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Prelude Therapeutics; Takeda
Consulting or Advisory Role - Amgen; ArriVent Biopharma; AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
Valentina Boni
Employment - Next Oncology
Honoraria - Tubulis GmbH
Consulting or Advisory Role - Tubulis GmbH
 
Rebecca Kristeleit
Honoraria - Abbvie; Abbvie; AstraZeneca; Basilea Pharmaceutical; Celcuity; Clovis Oncology; Eisai; Genmab; GlaxoSmithKline; Incyte; Leucid Bio; Merck Sharp & Dohme; MSD Oncology; Pharma&; Regeneron; Roche/Genentech; Shattuck Labs; Tesaro
Consulting or Advisory Role - Basilea; Clovis Oncology
Travel, Accommodations, Expenses - Basilea; Clovis Oncology; MSD Oncology
 
Debra Richardson
Honoraria - Zentalis
Consulting or Advisory Role - Abbvie; AstraZeneca; Daiichi Sankyo/UCB Japan; Eisai; Genmab; GlaxoSmithKline; Immunogen; Incyclix Bio; Mersana; ProfoundBio; Repare Therapeutics
Research Funding - A2A Pharmaceuticals (Inst); aadi (Inst); Acrivon Therapeutics (Inst); Allorian (Inst); Aravive (Inst); Arch Oncology (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); CanariaBio (Inst); Celsion (Inst); Clovis Oncology (Inst); DualityBio (Inst); GlaxoSmithKline (Inst); Hookipa Biotech (Inst); Immunogen/Abbvie (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Nimbus Therapeutics (Inst); Nurix (Inst); OnCusp Therapeutics (Inst); Plexxikon (Inst); PMV Pharma (Inst); ProfoundBio (Inst); Scorpion Therapeutics (Inst); Shattuck Labs (Inst); Tubulis GmbH (Inst); Valerion Therapeutics, LLC (Inst)
Travel, Accommodations, Expenses - Genmab; Society of Gynecologic Oncology
 
James Spicer
Leadership - APOBEC Discovery Ltd
Stock and Other Ownership Interests - Avacta Therapeutics; Epsilogen
Consulting or Advisory Role - AstraZeneca (Inst); BioNTch (Inst); Roche (Inst)
Research Funding - Achilles Therapeutics (Inst); AstraZeneca (Inst); BerGenBio (Inst); Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); IO Biotech (Inst); MSD (Inst); Roche (Inst); RS Oncology (Inst); Starpharma (Inst); Tubulis GmbH (Inst)
Patents, Royalties, Other Intellectual Property - Use of IgE antibodies for treatment of cancer
Travel, Accommodations, Expenses - MSD; Starpharma
 
Juergen Wolf
Honoraria - Abbvie; Amgen; Amgen Astellas BioPharma; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; DISCO Pharmaceuticals; Ellipses Pharma; Genmab; Janssen; Lilly; Merck; Mirati Therapeutics; MSD; Novartis; Nuvalent, Inc.; Pfizer; Regeneron; Roche; Seagen; Takeda; Turning Point Therapeutics; Zuelling Pharma
Consulting or Advisory Role - Abbvie; Amgen; Amgen; AstraZeneca; Bayer; Blueprint Medicines; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Ignyta; Janssen; Lilly; Loxo/Lilly; Merck; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Pfizer; Roche; Seagen; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb; Janssen; Novartis; Pfizer
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Janssen; Merck; Mirati Therapeutics; Novartis; Pfizer; Sanofi
 
Heather Scharpenseel
No Relationships to Disclose
 
Lea Ruge
No Relationships to Disclose
 
Frederik Herzberg
No Relationships to Disclose
 
Ignacio Matos
No Relationships to Disclose
 
Günter Fingerle-Rowson
Employment - Tubulis GmbH
Leadership - Tubulis GmbH
Stock and Other Ownership Interests - Tubulis GmbH
 
Ines Vasconcelos
No Relationships to Disclose
 
Sebastian Ochsenreither
Honoraria - AstraZeneca; BMS; immunocore; Janssen Oncology; Merck Serono; MSD
Consulting or Advisory Role - Immatics; immunocore; Janssen-Cilag; MSD; Pfizer
Research Funding - Bayer (Inst)
Patents, Royalties, Other Intellectual Property - Cyclin A1 as T-cell target
Travel, Accommodations, Expenses - Janssen Oncology; Merck Serono; Pfizer
Other Relationship - Ipsen
 
Alexander Starodub
No Relationships to Disclose